Nasza historia
Firma Ferring ewoluowała i rozwijała się, odkąd Frederik i Eva Paulsen założyli firmę w latach 50. XX wieku. Zespół zbudowany jest w duchu innowacyjności i dążeniu do tworzenia zmieniających życie terapii dla osób, które ich potrzebują.
Nasza historia i kamienie milowe
Odkryj historię firmy Ferring
Rozwój firmy Ferring to historia ludzi i peptydów. To dalekosiężna wizja kreatywnych naukowców, aby wykorzystać fundamentalną rolę hormonów peptydowych w kontrolowaniu wielu kluczowych procesów organizmu w celu opracowaniu medycyny na warunkach własnych organizmu. To także wizja przedsiębiorczości podszyta wyzwaniem aby te leki były dostępne na całym świecie.
Historyczna linia czasu
Ferring appoints Mirjam Mol-Arts to Executive Committee
-Ferring appoints Mirjam Mol-Arts to Executive Committee
Saint-Prex, Switzerland – 22 July, 2020 – Ferring Pharmaceuticals announced today that Mirjam Mol-Arts, previously Senior Vice President, Global Development, has been appointed to the position of Executive Vice President, Chief Science Officer and Chief Medical Officer. Per Falk, previously Chief Science Officer and President of the Executive Committee, will now focus exclusively on his role as President, leading the Executive Committee and Ferring into the company’s next phase of sustainable growth.
Since joining Ferring in 2018, Mirjam has had a major impact on Ferring’s R&D organisation, applying her knowledge and experience to strengthen the organisation’s capabilities and focus on patient centricity. Mirjam is a medical doctor with over 30 years’ experience in senior leadership roles spanning medical, research and development at MSD, Schering Plough, Organon and Solvay. Before joining Ferring, she was CEO of a newly formed science park with a focus on pharmaceutical innovation in the Netherlands.
The combined role of CSO and CMO will enable Ferring’s R&D and Medical organisations to work even more closely together, ensuring that the patient perspective drives each stage of the development journey.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.
For more information, please contact
Lindsey Rodger
Senior Manager, Corporate Communications
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.comFerring Pharmaceuticals successfully launches its inaugural Swiss Franc Bond offering for an amount of CHF 270 million
-Ferring Pharmaceuticals successfully launches its inaugural Swiss Franc Bond offering for an amount of CHF 270 million
Saint-Prex, Switzerland, 29th June 2020 – Ferring Pharmaceuticals announced the successful launch of its inaugural Swiss Franc Bond offering for a benchmark amount of CHF 270 million. This inaugural senior unsecured bond transaction issued by Ferring Holding SA has a fixed coupon rate of 1.05% per annum. The bond was issued at a price of 100.097% with a 5-year maturity on 9th July 2025, and will be listed on the SIX Swiss Exchange.
The offering attracted much interest from high-quality institutional investors and banks, demonstrating recognition of the company’s successful track record and solid cash generation. The company is rated as BBB (Credit Suisse) and Baa- (Fedafin), both with a stable outlook.
Dominic Moorhead, Chief Financial Officer of Ferring Pharmaceuticals, said “We are very happy with the successful outcome of our inaugural bond offering – and for a private company, entering a public capital market is a significant step. This is strong acknowledgement of the company’s achievements, and will enable us to firmly move forward with our next phase of growth.”
The net proceeds from the transaction will be used for general corporate purposes including repayment of debt. The issue was lead-managed by Credit Suisse AG and Basler Kantonalbank, with Banque Cantonale Vaudoise acting as co-manager.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and its products are available in 110 countries.
“Standing together against injustice” – a message from Per Falk, President and Chief Science Officer at Ferring
-“Standing together against injustice” – a message from Per Falk, President and Chief Science Officer at Ferring
The murder of George Floyd once again highlighted the deep racial injustice that exists in the US and around the world today. The violent death of an African-American at the hands of police has become an all too familiar scene, but what happened next was not. As I watch people come together to demand change across the world, I have been thinking about what I can do to actively oppose discrimination and oppression, and how we at Ferring can stand together against injustice.
So, what can someone like me do? Even though I abhor discrimination and oppression, have I helped enough throughout my life and career? These can be uncomfortable questions for those like me, who do not have first-hand experience of the injustices – large or small – that so many in the world endure every day for not being white, for not being a man, for not practising the ‘right’ religion, for not being heterosexual, or just for being poor. For those of us privileged enough not to experience discrimination in our daily lives, I believe that it is our responsibility to educate ourselves, to be open to hearing some uncomfortable truths, to recognise that we are part of the problem, and to find ways to become part of the solution.
I have also been reflecting on what Ferring can do to help bring about much-needed change – in the area of racial injustice and beyond. At Ferring, we are committed to building families of every shape and size, and we believe that no woman should die while giving life. Without gender equality, racial justice and health equality, we will never achieve these goals.
In our core area of fertility, black women and couples continue to be underserved. Women are underrepresented in medical research and clinical trials; this is even more pronounced if you are black, a member of an indigenous population or poor. Women in these communities are also more likely to have a poorer experience of healthcare during pregnancy, birth and post-delivery, experiencing higher levels of complications and mortality. In 2020, giving birth as a black woman is far more dangerous than giving birth as a white woman. Women in Sub-Saharan Africa and Southern Asia account for approximately 85% of global maternal deaths. In the US, black women are three times more likely to die than white women in childbirth.
At Ferring, we have committed to playing a role in reducing some of these disparities, in particular through our Project CHAMPION, aiming to reduce maternal mortality in low and lower-middle income countries. I am proud of this commitment but recognise that there is clearly much more to be done. Addressing disparities involves exposing structural inequalities across societies, education systems, healthcare systems and organisations. While these challenges may seem too big to solve, I believe that change starts with each of us, and with our own organisation.
At Ferring, we want to ensure that our work environment is safe, stimulating, rewarding and equal. However, I acknowledge that we can do more to be a truly diverse and inclusive company – an organisation where different minds, perspectives, backgrounds and skills create value and thrive together. Injustice and inequality are founded in conscious and unconscious bias. At Ferring, conscious bias will not be tolerated. At the same time, we must recognise that unconscious bias is part of all of us and come together to create awareness and ways to address this.
With this in mind, the Executive Committee will be discussing what actions Ferring can take to accelerate much needed changes in these areas. If you feel comfortable offering your own suggestions as to how we can reduce disparities in reproductive medicine and maternal health, and/or how we can do better at diversity and inclusion, we encourage you to share your valuable ideas.
As a personal commitment, it is my responsibility as the President of the Executive Committee to ensure that we learn, listen and take necessary action.
Per Falk
President & Chief Science OfficerFerring and Igenomix collaborate to advance care in reproductive medicine and maternal health
-Ferring and Igenomix collaborate to advance care in reproductive medicine and maternal health
- Collaboration aims to identify novel targets and disease mechanisms in infertility and pregnancy-related conditions, with the goal of developing innovative diagnostic and therapeutic strategies
- As part of the translational research collaboration, a new research hub will be created in Boston, bringing together scientists from both companies
- Collaboration combines Ferring’s therapeutic expertise with Igenomix’s diagnostic capabilities and demonstrates both companies’ commitment to building families worldwide
Saint-Prex, Switzerland and Valencia, Spain – Thursday 4 June 2020 – Ferring Pharmaceuticals and Igenomix today announced a two-year research collaboration aimed at the discovery of novel targets and disease mechanisms in infertility and pregnancy-related conditions, including preeclampsia, with the goal of developing innovative diagnostic and therapeutic strategies in these areas of high unmet need.
A new research hub will be created in Boston, bringing together scientists and expertise from both companies. The hub will focus on investigating molecular signatures, developing novel functional genomic systems and creating translational tools to study for embryo implantation, endometrial microbiome interaction and decidualization biology to drive innovative solutions for patients.
“Today, 1 in 6 couples worldwide are affected by fertility issues, with embryo implantation being a critical step to improving success rates in assisted reproduction technologies (ART) such as IVF. Furthermore, between 3 and 5% of all pregnancies are affected by preeclampsia1, a severe complication which increases the morbidity and mortality of both mother and baby,” said Joan-Carles Arce, Senior Vice President of Reproductive Medicine and Maternal Health, Ferring. “Through this collaboration, we aim to advance diagnostic testing and the discovery of candidate drug targets in these areas of high unmet need and ultimately help more people build healthy families worldwide.”
“This new research hub will connect Igenomix’s unique diagnostic capabilities with Ferring’s deep therapeutic expertise,” said Professor Carlos Simón, Head of Scientific Board of Igenomix Foundation and Project Lead for the new hub. “We believe this collaboration will accelerate scientific findings and improve conception rates at a time when significant progress is needed in preimplantation science to help more women and families experience healthy pregnancies.”
ENDS
About Fertility Issues
The World Health Organization defines infertility as a disease of the reproductive system defined by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse. Today, 1 in 6 couples worldwide are affected by fertility issues. Assisted Reproductive Technologies (ART) such as In Vitro Fertilisation (IVF) and Intracytoplasmic Sperm Injection (ICSI) can help couples who have problems conceiving naturally.
About Preeclampsia
Preeclampsia is a common and severe complication of pregnancy characterised by high blood pressure and multiple organ failure. It affects between 3% and 5% of all pregnancies in the US.1 There is a significant unmet need for an effective treatment for preeclampsia; currently the only ‘treatment’ is delivery of the baby.
Preeclampsia is responsible for approximately 20% of all preterm births2 and increases the morbidity and mortality of both mother and baby, especially in developing countries. An effective treatment would bring significant improvements in global infant and maternal health.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.
About Igenomix
Igenomix is a biotech company based in Valencia, Spain, specialized in reproductive genetics. Its expertise in fertility and its advanced research capacity situates the company as a worldwide referent in this area. Igenomix has 23 laboratories across the world and employs more than 400 professionals. Since the company launch in 2010, Igenomix has published more than 450 scientific papers and its communications have taken place during high level congresses such as ESHRE (European Society of Human Reproduction) or ASRM (American Society for Reproductive Medicine). Igenomix researchers have received numerous awards recognizing research and many of them share their knowledge and knowhow in leading US universities such as Stanford or Harvard.
For more information, please contact
Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.comLindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.comDulce Iborra
+34 647 942 875
dulce@laembajadora.esReferences
- CDC High Blood Pressure During Pregnancy 2020. Available at: https://www.cdc.gov/bloodpressure/pregnancy.htm
- Preeclampsia Foundation. FAQs. 2018. Available at: https://www.preeclampsia.org/history-of-preeclampsia/3-newsflash/301-faqs1
Ferring Statement on the COVID-19 (novel coronavirus disease) Pandemic and Reproductive Medicine
-Ferring Statement on the COVID-19 (novel coronavirus disease) Pandemic and Reproductive Medicine
Saint-Prex, Switzerland – 2 June, 2020
The health and safety of our patients, our employees and their families are Ferring’s number one priority. Ferring is committed to following appropriate global, regional and local medical authority guidance regarding the COVID-19 (novel coronavirus disease) situation to prevent infection spread and to keep patients, our employees and their families safe.
As the situation is now stabilising in many countries, Ferring is working with investigational sites to restart recruitment or continue our clinical trials in fertility, which were halted in impacted countries in March 2020 due to the pandemic. The restarting of clinic trials is in line with the current positions from scientific societies on patients seeking or undergoing fertility treatment, including from the European Society of Human Reproduction and Embryology (ESHRE) and the American Society of Reproductive Medicine (ASRM).
In addition to policies to protect our employees and prevent infection spread, we have also put in place plans to avoid disruption in manufacturing and ensure continuity of supply of our treatments to doctors and patients around the world. However, we unfortunately cannot rule out a future impact on our business as the situation continues to evolve rapidly.
We remain committed to building families worldwide and continue to work closely with healthcare professionals, patient groups and patients to advance treatment and care in reproductive medicine and maternal health.
Our thoughts are with the people and families affected by COVID-19 around the world, including our patients and those working tirelessly to address the pandemic.